AQUESTIVE THERAPEUTICS INC (AQST) Stock News
NASDAQ:AQST - Nasdaq - US03843E1047 - Common Stock - Currency: USD
AQST Latest News, Press Relases and Analysis
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion
German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing on expanding its research and development operations. According to BioNTech SE (NASDAQ:BNTX), its UK subsidiary has signed a grant agreement […]
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. aTyr Pharma, Inc. (NASDAQ:ATYR) was one of the stocks that was covered in that article. Wall Street analysts believe ATYR has a 485% upside potential over the next 12 months. aTyr Pharma, Inc. (NASDAQ:ATYR) stands as a pioneering biotherapeutics company dedicated to […]
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was one of the stocks that was covered in that article. Wall Street analysts believe LXRX has a 285% upside potential over the next 12 months. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company with a pioneering approach […]
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Aquestive Therapeutics (NASDAQ:AQST) was one of the stocks that was covered in that article. Wall Street analysts believe AQST has a 245% upside potential over the next 12 months. Aquestive Therapeutics, Inc. (NASDAQ:AQST) Upside Potential: 245.96% Aquestive Therapeutics (NASDAQ:AQST) stands out as […]
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -41.18% and 28.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CASI
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial...
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Is Dutch Bros Inc. (BROS) Among the Best Restaurant Stocks to Buy According to Hedge Funds?
We recently compiled a list of the 12 Best Restaurant Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Dutch Bros Inc. (NYSE:BROS) stands against the other best restaurant stocks. Restaurant stocks are businesses that own, run, and franchise full-service restaurants that sell prepared food and […]
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 4.20% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: COLL
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company...
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings
Stocktwits users are viewing the company's cash position, expectations for a late 2026 Anaphylm launch, and an upcoming trial as positive signals.
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if...
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water...
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
WARREN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States for the treatment of seizure clusters in patients ages 2 to 5
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
Cantor initiated coverage on Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with five commercialized products. The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis, and an earlier-stage epinephrine prodrug topical gel for various dermatology conditions. Cantor highlights that th
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences